Peder Andersson

Roles in PharmNovo: Business and scientific advisor.

Company: Biosergen AS

Resumé: Peder has a medical education from Copenhagen University from 1981. He did 6 years of hospital service within surgery, anesthesiology and internal medicine. He has more than 25 years of experience from large pharma, medium pharma and small/virtual biotech pharma. He has worked within oncology, diabetes, neurology, dermatology and was in his earlier days as consultant involved in testing cannabinol for neuropathic pain. He has established his own company and sold it to larger pharma. He has held senior positions in Orion Pharma, Novo Nordisk, Astion Pharma and Forward Pharma. He has held numerous meetings with both FDA, EMA, European agencies as well as Australian and New Zealand authorities. With Forward Pharma he was as CEO/COO heading all development and IP activities and was instrumental in the IPO on the NY Nasdaq October 2014 (raised 235M USD). Forward Pharma did also complete a license deal with Biogen Idec with a down payment of 1.25B USD. He holds currently the position as CEO at Biosergen AS, Norway.

Member of:

Business advisors

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.